Approaches to therapy for depressions in neurology: prospects for the use of agomelatine

Mild to moderate cognitive impairment (CI) in elderly and senile age may be caused by various neuropsychiatric diseases, including Alzheimer's disease (AD) and depression. The literature review presents the mechanisms of CI development in AD and depressive disorders, as well as their course, prognosis, and differential diagnosis. Mild and moderate depressions in AD, their clinical variants, course and treatment approaches are described. Treatment for CI is shown to focus on therapy of the underlying disease, in which the former occurs. Antidepressants are used to treat depression and depressive disorders in AD, by taking into account the efficacy and tolerability of the drugs at old age.

show abstract

Cognitive impairment in depression and Alzheimer's disease: differential diagnosis and approaches to therapy

Tyuvina

Прохорова

Maksimova

et al. 2019

RJTAO

View full text Add to dashboard Cite

show abstract

From accurate diagnosis to targeted therapy: depression in general medical practice

Петрова

2021

RJTAO

View full text Add to dashboard Cite

Objective: to analyze the diagnostic significance of clinical and phenomenological characteristics of affective disorders in patients with chronic somatic pathology.Patients and methods. The analysis included the results of a clinical evaluation of 131 patients with chronic somatic pathology, including 96 patients suffering from cardiovascular diseases and 35 patients with cerebral small vessel disease. Clinical assessment included Primary care evaluation of mental disorders (PRIME-MD) and Hamilton Depression Rating Scale.Results and discussion. Despite the significant frequency and transparent clinical symptoms, general practitioners diagnosed mental disorders in only 30% of patients with depression. We observed a higher prevalence of somatic rather than psychological complaints during the clinical survey. According to the screening using PRIME-MD, 74% of patients were diagnosed with mood disorders, anxiety, and somatoform disorders. We also noted their significant comorbidity with a predominance of a depression and anxiety combination (p < 0.001). Hypertensive patients had the highest depression prevalence (87%) and severity. Moderate depression was the most frequent diagnosis in the study participants, corresponding to major depressive disorder (61.5%).Conclusion. In general, the symptoms of anhedonia, depression, and anxiety were most pronounced in patients with affective disorders. The high prevalence of somatic symptoms complicates depression evaluation. It is possible to highlight depression and anhedonia as significant symptoms for the detection of depression in patients with somatic disorders.

show abstract

Treatment of mixed anxiety and depressive disorder: results from a observational study of the efficacy and tolerability of agomelatine

Petelin

Niinoya

Sorokina

et al. 2021

RJTAO

Self Cite

View full text Add to dashboard Cite

Objective: to study the efficacy, safety and tolerability of agomelatine in mixed anxiety and depressive disorder.Patients and methods. Agomelatine was administered to 30 patients diagnosed with mixed anxiety and depressive disorder for 3 months. The patients' condition was assessed using a battery of psychometric methods – the Hamilton Depression Scale, the Hamilton Anxiety Scale, and a short form of the SF-12v2 quality of life questionnaire.Results and discussion. It was shown that agomelatine effectively reduces both symptoms of depression and anxiety, begins to have a therapeutic effect a week after the start of administration, however, the drug shows the best clinical effect when administered for a period of three months or more. The predictors of complete remission on agomelatine therapy in this sample were: the presence of sleep disorders (early and medium, but not late insomnia), a greater severity of somatized anxiety, the presence of complaints of decreased workplace performance and activity.Conclusion. Our study has shown that agomelatine is an effective, safe and well-tolerated drug in the treatment of mixed anxiety and depressive disorder.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Approaches to therapy for depressions in neurology: prospects for the use of agomelatine

Cited by 7 publications

References 59 publications

Cognitive impairment in depression and Alzheimer's disease: differential diagnosis and approaches to therapy

Cognitive impairment in depression and Alzheimer's disease: differential diagnosis and approaches to therapy

From accurate diagnosis to targeted therapy: depression in general medical practice

Treatment of mixed anxiety and depressive disorder: results from a observational study of the efficacy and tolerability of agomelatine

Contact Info

Product

Resources

About